

Tanuja Chitnis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7132033/tanuja-chitnis-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301
papers

14,485
citations

56
h-index

113
g-index

321
ext. papers

17,785
ext. citations

6.3
avg, IF

6.55
L-index

#	Paper	IF	Citations
301	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069926	5	0
300	Serum NFL levels in the first five years predict 10-year thalamic fraction in patients with MS.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022 , 8, 20552173211069348	2	1
299	Generating real-world data from health records: design of a patient-centric study in multiple sclerosis using a commercial health records platform.. <i>JAMIA Open</i> , 2022 , 5, ooab110	2.9	0
298	How patients with multiple sclerosis acquire disability.. <i>Brain</i> , 2022 ,	11.2	10
297	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103333	4	0
296	Preventing Multiple Sclerosis: The Pediatric Perspective.. <i>Frontiers in Neurology</i> , 2022 , 13, 802380	4.1	1
295	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG Study.. <i>BMJ Neurology Open</i> , 2022 , 4, e000215	1.5	
294	Targeting Epstein-Barr virus to treat MS.. <i>Med</i> , 2022 , 3, 159-161	31.7	
293	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 62, 103793	4	0
292	Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 63, 103861	4	0
291	Anti-CGRP therapies for migraine in multiple sclerosis patients.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221096353	5	0
290	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1814-1822	5	6
289	Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. <i>JAMA Network Open</i> , 2021 , 4, e2134627	10.4	3
288	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. <i>Quality of Life Research</i> , 2021 , 1	3.7	0
287	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2021 , 20, 1001-1011	24.1	5
286	Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103311	4	
285	An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial. <i>International Journal of MS Care</i> , 2021 , 23, 128-134	2.3	1

284	Interplay Between Endocrine Disruptors and Immunity: Implications for Diseases of Autoreactive Etiology. <i>Frontiers in Pharmacology</i> , 2021 , 12, 626107	5.6	0
283	Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disorders. <i>Nutritional Neuroscience</i> , 2021 , 1-7	3.6	0
282	Gut Microbiome in Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 1195-1211	9.4	27
281	Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 2055217321999070	2	0
280	Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211007739	5	
279	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211015503	2	1
278	The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211007523	2	
277	Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum. <i>Frontiers in Neurology</i> , 2021 , 12, 691683	4.1	1
276	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102910	4	
275	Secondary Progressive Multiple Sclerosis: New Insights. <i>Neurology</i> , 2021 , 97, 378-388	6.5	14
274	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 593-602	5	4
273	Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 79-89	5	2
272	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 922-932	5	5
271	is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	8
270	Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. <i>JAMA Neurology</i> , 2021 , 78, 241-246	17.2	10
269	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021 , 31, 388-393	2.8	3
268	Clinical Approach to Pediatric Demyelinating Disease 2021 , 469-482		
267	Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity. <i>Journal of Patient Experience</i> , 2021 , 8, 23743735211039319	1.3	

266	Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. <i>Lancet Neurology, The</i> , 2021 , 20, 136-149	24.1	19
265	Microstructural Changes in the Left Mesocorticolimbic Pathway are Associated with the Comorbid Development of Fatigue and Depression in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021 , 31, 501-507 ^{2,8}		3
264	Leveraging electronic health records data to predict multiple sclerosis disease activity. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 800-810	5.3	4
263	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
262	Gut microbiome is associated with multiple sclerosis activity in children. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1867-1883	5.3	6
261	Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103277	4	2
260	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021 , 20, 762-772		37
259	Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 54, 103086	4	1
258	Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 631-638	5.3	3
257	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	1
256	1128 Sleep Apnea and Periodic Limb Movements are Highly Prevalent in Patients With Multiple Sclerosis. <i>Sleep</i> , 2020 , 43, A429-A430	1.1	
255	Blood neurofilament light: a critical review of its application to neurologic disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2508-2523	5.3	39
254	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102251	4	46
253	Down Syndrome Disintegrative Disorder: A Clinical Regression Syndrome of Increasing Importance. <i>Pediatrics</i> , 2020 , 145,	7.4	8
252	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 945-955	5.3	15
251	Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review. <i>JAMA Internal Medicine</i> , 2020 , 180, 574-583	11.5	68
250	Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. <i>Nature Reviews Neurology</i> , 2020 , 16, 154-170	15	37
249	A roadmap to precision medicine for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 522-532	5	12

248	Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 88, 42-55	9.4	26
247	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 483-492	5.5	10
246	Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 509-516	4.3	8
245	Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2020 , 2020, 5471987	1.1	
244	Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101944	4	2
243	Association Between Cigarette Smoking and Multiple Sclerosis: A Review. <i>JAMA Neurology</i> , 2020 , 77, 245-253	17.2	25
242	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1938-1947	5	8
241	Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. <i>Journal of Psychosomatic Research</i> , 2020 , 138, 110252	4.1	11
240	Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. <i>Npj Digital Medicine</i> , 2020 , 3, 135	15.7	6
239	Magnetic resonance imaging at baseline and follow-up to differentiate between pediatric monophasic acquired CNS demyelination and MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102590	4	2
238	Opposing and potentially antagonistic effects of BMP and TGF- β in multiple sclerosis: The "Yin and Yang" of neuro-immune Signaling. <i>Journal of Neuroimmunology</i> , 2020 , 347, 577358	3.5	2
237	Pediatric Multiple Sclerosis Severity Score in a large US cohort. <i>Neurology</i> , 2020 , 95, e1844-e1853	6.5	3
236	Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases. <i>Scientific Reports</i> , 2020 , 10, 12405	4.9	2
235	MRI activity in MS and completed pregnancy: Data from a tertiary academic center. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	4
234	Improved relapse recovery in paediatric compared to adult multiple sclerosis. <i>Brain</i> , 2020 , 143, 2733-2741	11.2	20
233	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	9
232	Consistent control of disease activity with fingolimod versus IFN β 1a in paediatric-onset multiple sclerosis: further insights from PARADIG. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 58-66	5.5	14
231	Vitamin D genes influence MS relapses in children. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 894-901	5	12

230	Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 21-22	5	2
229	Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1410-1419	5	11
228	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1708-1718	5	15
227	Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. <i>Epilepsy and Behavior Reports</i> , 2019 , 12, 100326	1.3	7
226	Adipokines are associated with pediatric multiple sclerosis risk and course. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101384	4	8
225	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
224	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019 , 15, e1007808	6	20
223	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019 , 403, 38-43	3.2	10
222	miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1053-1061	5.3	4
221	Multiple sclerosis and sarcoidosis: A case for coexistence. <i>Neurology: Clinical Practice</i> , 2019 , 9, 218-227	1.7	5
220	Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. <i>Neurology</i> , 2019 , 92, e2538-e2549	6.5	38
219	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319828400 ²		4
218	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019 , 177, 231-242	56.2	91
217	Total intake of different minerals and the risk of multiple sclerosis. <i>Neurology</i> , 2019 , 92, e2127-e2135	6.5	3
216	Strokelike Episodes in a Patient With Chronic Gait Abnormalities. <i>JAMA Neurology</i> , 2019 , 76, 621-622	17.2	1
215	Time between expanded disability status scale (EDSS) scores. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 30, 98-103	4	7
214	The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. <i>BMC Neurology</i> , 2019 , 19, 23	3.1	33
213	Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials. <i>Neurology and Therapy</i> , 2019 , 8, 461-475	4.6	7

212	Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody. <i>Neuropediatrics</i> , 2019 , 50, 273-279	1.6	11
211	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 35, 119-127 ⁴		13
210	History of fatigue in multiple sclerosis is associated with grey matter atrophy. <i>Scientific Reports</i> , 2019 , 9, 14781	4.9	13
209	School performance and psychiatric morbidity 6 years after pediatric acute disseminated encephalomyelitis: A nationwide population-based cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101425	4	3
208	Rotating night shift work and risk of multiple sclerosis in the Nurses' Health Studies. <i>Occupational and Environmental Medicine</i> , 2019 , 76, 733-738	2.1	4
207	Pediatric Central Nervous System Demyelinating Diseases. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019 , 25, 793-814	3	6
206	T Cell-Secreted XCL1 Mediates Anti-CD3-Induced Oral Tolerance. <i>Journal of Immunology</i> , 2019 , 203, 2621-2629	5.3	10
205	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. <i>Npj Digital Medicine</i> , 2019 , 2, 123	15.7	21
204	Pan-viral serology implicates enteroviruses in acute flaccid myelitis. <i>Nature Medicine</i> , 2019 , 25, 1748-1753 ^{0.5}	30.5	54
203	A young man in "double-trouble": Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e526	9.1	0
202	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 113-121	1.9	11
201	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019 , 34, 148-152	2.5	2
200	Clinical Course and Treatment in MOG Antibody Seropositive Children: A Case Series. <i>Journal of Pediatric Neurology</i> , 2019 , 17, 031-037	0.2	1
199	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1791-1799	5	1
198	Diet quality and risk of multiple sclerosis in two cohorts of US women. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1773-1780	5	14
197	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 65-73	4	5
196	Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 344-351	5	4
195	Correlating serum micrnas and clinical parameters in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2018 , 58, 261-269	3.4	52

194	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 103-107	4	
193	The role of testosterone in MS risk and course. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 36-41	5	19
192	Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 20, 51-57	4	14
191	Pediatric Neuromyelitis Optica Spectrum Disorders. <i>Current Treatment Options in Neurology</i> , 2018 , 20, 19	4.4	24
190	Oral contraceptives and MS disease activity in a contemporary real-world cohort. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 227-230	5	9
189	Dietary factors and pediatric multiple sclerosis: A case-control study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1067-1076	5	17
188	Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1126-1130	5	4
187	Genetic risk factors for pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1825-1834	5	25
186	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 28-33	5.5	45
185	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1485-1498	5.98	14
184	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. <i>ENeurologicalSci</i> , 2018 , 12, 42-46	2.1	9
183	Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2018 , 392, 94-99	3.2	7
182	Fingolimod® Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. <i>Journal of Neuroimaging</i> , 2018 , 28, 399-405	2.8	8
181	Pediatric Multiple Sclerosis 2018 , 277-294		
180	Identification of MS-specific serum miRNAs in an international multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e491	9.1	34
179	A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018 , 20, 136-141	2.3	6
178	Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018 , 28, 273-277	2.8	15
177	Beyond the band: A biomarker for pediatric MS?. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1655-1656	5	

176	Heterogeneity in association of remote herpesvirus infections and pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1222-1228	5.3	17
175	Urban air quality and associations with pediatric multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1146-1153	5.3	21
174	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. <i>Neurology</i> , 2018 , 91, e1778-e1787	6.5	29
173	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1478-1491	5.3	69
172	Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. <i>Journal of the Neurological Sciences</i> , 2018 , 394, 127-131	3.2	7
171	Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients. <i>Journal of Neurology</i> , 2018 , 265, 2688-2694	5.5	11
170	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018 , 379, 1017-1027	59.2	144
169	Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318778610	2	15
168	Joint assessment of dependent discrete disease state processes. <i>Statistical Methods in Medical Research</i> , 2017 , 26, 1182-1198	2.3	2
167	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. <i>JAMA Neurology</i> , 2017 , 74, 275-285	17.2	37
166	Child Neurology: Neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2017 , 88, e10-e13	6.5	7
165	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017 , 127, 971-980 ²		10
164	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 371-375	3.2	3
163	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2017 , 27, 481-485	2.8	23
162	Polyunsaturated fatty acids and the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1830-1838	4.8	48
161	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017 , 4, e339	9.1	20
160	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017 , 88, 1623-1629	6.5	97
159	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. <i>Pediatrics</i> , 2017 , 139,	7.4	22

158	Acute disseminated encephalomyelitis in China, Singapore and Japan: a comparison with the USA. <i>European Journal of Neurology</i> , 2017 , 24, 391-396	6	6
157	Exposure to particulate matter air pollution and risk of multiple sclerosis in two large cohorts of US nurses. <i>Environment International</i> , 2017 , 109, 64-72	12.9	32
156	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2017 , 89, 2238-2244	3.4	38
155	CNS inflammation and neurodegeneration. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3577-3587	15.9	214
154	No association between dietary sodium intake and the risk of multiple sclerosis. <i>Neurology</i> , 2017 , 89, 1322-1329	6.5	28
153	Examining the contributions of environmental quality to pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 164-169	4	17
152	Wearable biosensors to monitor disability in multiple sclerosis. <i>Neurology: Clinical Practice</i> , 2017 , 7, 354-362	3.6	24
151	Depression and fatigue in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017 , 380, 236-241	3.2	32
150	Child Neurology: Primary angiitis of the CNS. <i>Neurology</i> , 2017 , 89, e268-e271	6.5	4
149	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017 , 383, 221-229	3.2	13
148	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 196-201	4	12
147	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 47-53	4	12
146	Exploration of machine learning techniques in predicting multiple sclerosis disease course. <i>PLoS ONE</i> , 2017 , 12, e0174866	3.7	71
145	MS in Adolescence 2017 , 73-83		
144	Clinical and MRI phenotype of children with MOG antibodies. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 174-84	5	96
143	Women's experiences of menopause in an online MS cohort: A case series. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 9, 56-9	4	9
142	Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. <i>Neurology</i> , 2016 , 87, S12-9	6.5	33
141	Neuromyelitis optica spectrum disorders in children and adolescents. <i>Neurology</i> , 2016 , 87, S59-66	6.5	62

140	International Pediatric MS Study Group Global Members Symposium report. <i>Neurology</i> , 2016 , 87, S110-66.5		16
139	Pediatric multiple sclerosis: Escalation and emerging treatments. <i>Neurology</i> , 2016 , 87, S103-9	6.5	33
138	Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset. <i>Neurology: Genetics</i> , 2016 , 2, e88	3.8	13
137	Immunology of neuromyelitis optica during pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e288	9.1	32
136	Alterations of the human gut microbiome in multiple sclerosis. <i>Nature Communications</i> , 2016 , 7, 12015	17.4	632
135	Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 8, 136-40	4	24
134	Use of Disease-Modifying Therapies in Pediatric MS. <i>Current Treatment Options in Neurology</i> , 2016 , 18, 36	4.4	31
133	Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 354-61	5	30
132	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 153-7	3.2	110
131	The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2016 , 26, 184-7	2.8	11
130	Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 935-43	5	41
129	Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1841-1849	5	32
128	Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. <i>Neurology</i> , 2016 , 86, 245-52	6.5	75
127	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. <i>Annals of Neurology</i> , 2016 , 79, 178-89	9.4	30
126	Characteristics of Children and Adolescents With Multiple Sclerosis. <i>Pediatrics</i> , 2016 , 138,	7.4	52
125	Experience with long-term rituximab use in a multiple sclerosis clinic. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016 , 2, 2055217316672100	2	15
124	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1350-1353	5.5	43
123	Risk attitudes and risk perceptions in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016 , 2, 2055217316665406	2	7

122	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 897-907	5.3	47
121	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 87-92	4	43
120	Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study. <i>Neurology</i> , 2016 , 86, 2085-93	6.5	70
119	Pediatric Multiple Sclerosis. <i>Seminars in Neurology</i> , 2016 , 36, 148-53	3.2	16
118	Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis. <i>Neurology</i> , 2016 , 87, 1457-1463	6.5	24
117	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e267	9.1	50
116	Physical activity and the incidence of multiple sclerosis. <i>Neurology</i> , 2016 , 87, 1770-1776	6.5	26
115	Progression rates and sample size estimates for PPMS based on the CLIMB study population. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 180-8	5	9
114	The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps. <i>Journal of Child Neurology</i> , 2015 , 30, 1381-7	2.5	16
113	Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients. <i>Artificial Intelligence in Medicine</i> , 2015 , 65, 79-88	7.4	6
112	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015 , 85, 177-89	6.5	2255
111	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. <i>NeuroImage</i> , 2015 , 119, 81-8	7.9	6
110	Demographic and clinical features of neuromyelitis optica: A review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 845-53	5	214
109	Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. <i>JAMA Neurology</i> , 2015 , 72, 152-8	17.2	260
108	The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. <i>Neurology</i> , 2015 , 85, 1209-13	6.5	12
107	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015 , 262, 2425-32	5.5	19
106	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. <i>NeuroImage: Clinical</i> , 2015 , 8, 606-10	5.3	19
105	Domain Induced Dirichlet Mixture of Gaussian Processes: An Application to Predicting Disease Progression in Multiple Sclerosis Patients 2015 ,		2

104	Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. <i>Journal of Neuroinflammation</i> , 2015 , 12, 245	10.1	23
103	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015 , 72, 815-22	17.2	49
102	Effect of vitamin D on MS activity by disease-modifying therapy class. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e167	9.1	34
101	Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 598-606	4	10
100	Patients report worse MS symptoms after menopause: findings from an online cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 18-24	4	30
99	The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 520-6	5	113
98	Protective environmental factors for neuromyelitis optica. <i>Neurology</i> , 2014 , 83, 1923-9	6.5	18
97	Balo concentric sclerosis in children: a case series. <i>Journal of Child Neurology</i> , 2014 , 29, 603-7	2.5	4
96	Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 438-44	5	28
95	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1381-90	5	24
94	Menopause in multiple sclerosis: therapeutic considerations. <i>Journal of Neurology</i> , 2014 , 261, 1257-68	5.5	14
93	Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1502-10	5	56
92	Low testosterone is associated with disability in men with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1584-92	5	68
91	Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 757-60	5	4
90	An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. <i>NeuroReport</i> , 2014 , 25, 1156-61	1.7	18
89	Functional relapses in pediatric multiple sclerosis. <i>Journal of Child Neurology</i> , 2014 , 29, 943-6	2.5	3
88	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. <i>Neurology</i> , 2014 , 82, 2173-9	6.5	39
87	Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 186-93	4	80

86	Treatment satisfaction in multiple sclerosis. <i>International Journal of MS Care</i> , 2014 , 16, 68-75	2.3	26
85	Increased Th17 response to myelin peptides in pediatric MS. <i>Clinical Immunology</i> , 2013 , 146, 176-84	9	25
84	No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. <i>BMC Neurology</i> , 2013 , 13, 73	3.1	22
83	Role of puberty in multiple sclerosis risk and course. <i>Clinical Immunology</i> , 2013 , 149, 192-200	9	50
82	Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1726-33	5	39
81	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1261-7	5	646
80	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. <i>BMC Neurology</i> , 2013 , 13, 173	3.1	2
79	Increased leptin and A-FABP levels in relapsing and progressive forms of MS. <i>BMC Neurology</i> , 2013 , 13, 172	3.1	18
78	Disease-modifying therapy of pediatric multiple sclerosis. <i>Neurotherapeutics</i> , 2013 , 10, 89-96	6.4	27
77	Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. <i>Annals of Neurology</i> , 2013 , 73, 729-40	9.4	176
76	Diffusion tensor analysis of pediatric multiple sclerosis and clinically isolated syndromes. <i>American Journal of Neuroradiology</i> , 2013 , 34, 417-23	4.4	26
75	Sexual disparities in the incidence and course of MS. <i>Clinical Immunology</i> , 2013 , 149, 201-10	9	64
74	Pediatric demyelinating diseases. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013 , 19, 1023-45	3	5
73	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 891-5	5	27
72	Paediatric MS is the same disease as adult MS: no. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1255-6	5	7
71	Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis International</i> , 2013 , 2013, 189624	1.1	32
70	Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. <i>Journal of Child Neurology</i> , 2013 , 28, 102-7	2.5	103
69	Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. <i>PLoS ONE</i> , 2013 , 8, e59707	3.7	47

68	Modeling disease severity in multiple sclerosis using electronic health records. <i>PLoS ONE</i> , 2013 , 8, e78923	3.7	47
67	Inflammatory demyelinating diseases in children: an update. <i>Minerva Pediatrica</i> , 2013 , 65, 307-23	1.6	
66	CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia?. <i>Neurology</i> , 2012 , 78, 221-3	6.5	19
65	The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. <i>Quality of Life Research</i> , 2012 , 21, 1677-84	3.7	22
64	Pathogenesis of pediatric multiple sclerosis. <i>Journal of Child Neurology</i> , 2012 , 27, 1394-407	2.5	22
63	Pediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis 2012 , 101-135		
62	Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. <i>Journal of the Neurological Sciences</i> , 2012 , 315, 49-54	3.2	13
61	Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. <i>Value in Health</i> , 2012 , 15, 1029-35	3.3	98
60	Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 116-27	5	149
59	The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1579-85	4.4	58
58	Effect of gender on late-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1472-9	5	76
57	Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 38-43	5.5	54
56	Daclizumab use in patients with pediatric multiple sclerosis. <i>Archives of Neurology</i> , 2012 , 69, 78-81		36
55	Parainfectious and Autoimmune Disorders 2012 , 3543-3554		
54	Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 303, 109-13	3.2	7
53	Pediatric multiple sclerosis. <i>Neurologic Clinics</i> , 2011 , 29, 481-505	4.5	37
52	Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. <i>Journal of Neuroimmunology</i> , 2011 , 233, 168-74	3.5	36
51	Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. <i>Journal of Neurology</i> , 2011 , 258, 479-85	5.5	50

50	Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. <i>Journal of Neurology</i> , 2011 , 258, 1812-9	5.5	9
49	Gestational vitamin D and the risk of multiple sclerosis in offspring. <i>Annals of Neurology</i> , 2011 , 70, 30-40	9.4	105
48	Demographic and clinical characteristics of malignant multiple sclerosis. <i>Neurology</i> , 2011 , 76, 1996-2001	6.5	56
47	Patient reported outcomes in benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 876-84	5	11
46	Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. <i>Archives of Neurology</i> , 2011 , 68, 437-44		86
45	A putative Alzheimer® disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. <i>PLoS ONE</i> , 2010 , 5, e14169	3.7	15
44	Tract-based analysis of callosal, projection, and association pathways in pediatric patients with multiple sclerosis: a preliminary study. <i>American Journal of Neuroradiology</i> , 2010 , 31, 121-8	4.4	54
43	CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. <i>Journal of Neuroscience</i> , 2010 , 30, 2025-38	6.6	60
42	Younger children with MS have a distinct CSF inflammatory profile at disease onset. <i>Neurology</i> , 2010 , 74, 399-405	6.5	102
41	A method for evaluating treatment switching criteria in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1483-9	5	18
40	Treatment of multiple sclerosis in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 505-20	4	21
39	Cyclophosphamide therapy in pediatric multiple sclerosis. <i>Neurology</i> , 2009 , 72, 2076-82	6.5	107
38	Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. <i>Journal of Immunology</i> , 2009 , 183, 4067-76	5.3	161
37	Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 54-9		264
36	Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 627-31	5	179
35	Prenatal and perinatal factors and risk of multiple sclerosis. <i>Epidemiology</i> , 2009 , 20, 611-8	3.1	60
34	Smoking and disease progression in multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 858-64		142
33	The relationship between handedness and risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 587-92	5	16

32	A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2009 , 206, 76-85	3.5	8
31	Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. <i>Journal of the Neurological Sciences</i> , 2009 , 279, 99-105	3.2	65
30	Pediatric multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009 , 5, 621-31	15	93
29	Body size and risk of MS in two cohorts of US women. <i>Neurology</i> , 2009 , 73, 1543-50	6.5	297
28	Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. <i>American Journal of Neuroradiology</i> , 2009 , 30, 1731-9	4.4	11
27	Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. <i>American Journal of Pathology</i> , 2008 , 173, 411-22	5.8	47
26	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. <i>Nature Medicine</i> , 2007 , 13, 211-7	50.5	266
25	The role of CD4 T cells in the pathogenesis of multiple sclerosis. <i>International Review of Neurobiology</i> , 2007 , 79, 43-72	4.4	105
24	Treatment of pediatric multiple sclerosis and variants. <i>Neurology</i> , 2007 , 68, S54-65	6.5	83
23	Challenges in the classification of pediatric multiple sclerosis and future directions. <i>Neurology</i> , 2007 , 68, S70-4	6.5	22
22	Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. <i>American Journal of Pathology</i> , 2007 , 170, 1695-712	5.8	128
21	Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. <i>Archives of Neurology</i> , 2006 , 63, 25-33		67
20	Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 2006 , 176, 3480-9	5.3	104
19	Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. <i>Journal of Neuroscience</i> , 2006 , 26, 9794-804	6.6	119
18	Pediatric multiple sclerosis. <i>Neurologist</i> , 2006 , 12, 299-310	1.6	16
17	Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2005 , 5, 11-26		13
16	Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. <i>Journal of Immunology</i> , 2004 , 172, 4260-5	5.3	21
15	Regulation of postsurgical fibrosis by the programmed death-1 inhibitory pathway. <i>Journal of Immunology</i> , 2004 , 172, 5774-81	5.3	22

14	Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. <i>Immunologic Research</i> , 2003 , 28, 223-39	4.3	53
13	Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. <i>Journal of Neuroimmunology</i> , 2003 , 136, 140-8	3.5	80
12	20. Immunologic neuromuscular disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2003 , 111, S659-68	1.5	15
11	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Journal of Allergy and Clinical Immunology</i> , 2003 , 112, 837-49; quiz 850	11.5	39
10	The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. <i>Journal of Experimental Medicine</i> , 2003 , 198, 63-9	16.6	592
9	A novel mechanism for the immunomodulatory functions of class II MHC-derived peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1053-65	12.7	7
8	Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2003 , 198, 71-8	16.6	393
7	Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. <i>Journal of Clinical Investigation</i> , 2003 , 112, 1037-48	15.9	204
6	CD4+ T cells regulate surgical and postinfectious adhesion formation. <i>Journal of Experimental Medicine</i> , 2002 , 195, 1471-8	16.6	79
5	CD28-independent induction of experimental autoimmune encephalomyelitis. <i>Journal of Clinical Investigation</i> , 2001 , 107, 575-83	15.9	61
4	Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. <i>Journal of Clinical Investigation</i> , 2001 , 108, 739-47	15.9	93
3	Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. <i>Journal of Clinical Investigation</i> , 2001 , 108, 739-747	15.9	152
2	Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. <i>Journal of Clinical Investigation</i> , 2000 , 105, 1109-16	15.9	34
1	Pediatric MS: biological presentation and research update	157-168	1